Kenny Walter

Matthew Weir, MD, discusses the START-CKD trial at Kidney Week.

In an abstract presented at Kidney Week, investigators discuss the differences in treatments along different demographical lines.

During Kidney Week, investigators present data showing that canagliflozin could be beneficial for patients across various levels of kidney function.

Investigators from many different fields, including nephrology, oncology, and cardiology, come together to collaborate at Kidney Week.

During Kidney Week, Christine Liu, MD, discusses some of the issues geriatric patients face.

Brad Rovin, MD, discusses the NOBILITY study while at Kidney Week and what its impact on patients with lupus nephritis will be.

Kenneth Mahaffey, MD, discussed during Kidney Week the CREDENCE trial and what the link is between the 3 different medical fields.

Investigators present new data from the OLYMPUS and ROCKIES trials during Kidney Week.

Katja Gist, DO, discusses better ways to prevent acute kidney injuries in pediatric patients who have cardiac surgery.

Brad Rovin, MD, of The Ohio State University, discusses during Kidney Week what is needed for better outcomes for patients with lupus nephritis.

Investigators test a potential treatment for the most common hereditary kidney disease during Kidney Week.

Miguel Regueiro, MD and George Khoudari, MD, both of the Cleveland Clinic, discuss predictors of colectomies for IBD-patients.

Despite a higher genetic risk, investigators link physical activity with decreased odds for developing depression.

New data shows that selective serotonin reuptake inhibitors reduce obsessive-compulsive symptoms for children and adolescents with autism spectrum disorders.

The new vaccine is expected to be available for the 2020-2021 influenza season.

During the ACG meeting, investigators tested a subcutaneous form of vedolizumab to treat ulcerative colitis.

Miguel Regueiro, MD, of the Cleveland Clinic, talks about some of the medications that treat ulcerative colitis and Crohn's disease at the annual ACG meeting.

With the recent FDA approval, ustekinumab could be the first choice to treat ulcerative colitis.

In a study presented at the ACG 2019 meeting, investigators discuss their groundbreaking work on inflammatory bowel disease.

In a pioneer study, investigators investigate if cannabis users had less incidence of pancreatic necrosis and/or pancreatic/peripancreatic fluid collections.

Investigators test a subcutaneous version of vedolizumab for different durations to treat ulcerative colitis.

At the annual ACG meeting, Carlos Romero-Marrero, MD and Mohammad Alomari, MD discuss what can be done to reduce the drug use rate for high risk patients.

In a study presented at the annual ACG meeting, investigators find that 1L vedolizumab does not impact the effectiveness of subsequent anti-TNF treatment.

In a poster presented at the annual ACG meeting, investigators estimate the prevalence of medication use by drug class for IBD-patients based on age.

At the annual ACG meeting, Maria Abreu, MD, explains how drugs like ustekinumab can treat patients with Crohn's disease and patients with ulcerative colitis, while other medications do not work as well in both diseases.

Roberto Simons-Linares, MD, presents new data at the annual ACG meeting on the association between hepatitis viral infections and acute pancreatitis.

In a late breaking clinical trial at ACG 2019, investigators say AK002 shows promise in treating patients with EGID.

Investigators present data from a new study showing that RHB-104 can effectively combat MAP infections for patients with moderately to severely active Crohn’s disease.

During the annual ACG meeting, Roberto Simons-Linares, MD explained how cannabis use impacts the fluids of patients suffering from acute necrotizing pancreatitis.

In a retrospective study presented at the annual ACG meeting, investigators examine sex and ethnicity data involving linkage to care for hepatitis C virus patients.